AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7778622
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (0.5 mg, three doses 6 hours apart)
Trial: 7778622
Drug: Estradiol cream
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol cream (4 mg, three doses 6 hours apart)
Trial: 7778622
Drug: Oxytocin (at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxytocin (at induction per protocol with an infusion pump)
Trial: 24503408
Drug: 10 mg/mL
RxNorm normalized name: urea 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/mL posterior subtenon injection of nanoparticle carboplatin
Trial: 9098274
Drug: Corticosteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid treatment after trabeculectomy
Trial: 9098274
Drug: Nonsteroid treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroid treatment after trabeculectomy
Trial: 31788828
Drug: Combination thulium
RxNorm normalized name: thulium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination thulium laser and photodynamic therapy (TL-PDT)
Trial: 30978265
Drug: Aprepitant therapy
RxNorm normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprepitant therapy
Trial: 28449280
Drug: ondansetron 150
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ondansetron 150 μg.kg‐1
Trial: 28449280
Drug: droperidol 10
RxNorm normalized name: droperidol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: droperidol 10 μg.kg‐1
Trial: 24084214
Drug: Irbesartan (angiotensin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Irbesartan (angiotensin receptor blocker)
Trial: 24084214
Drug: Atenolol (beta-adrenergic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol (beta-adrenergic receptor blocker)
Trial: 16292089
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose of omeprazole (20 mg; 60 mg/3 days)
Trial: 16292089
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of omeprazole (80 mg bolus + 8 mg/h; 652 mg/3 days)
Trial: 16292089
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose of omeprazole
Trial: 16292089
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of omeprazole
Trial: 12465390
Drug: HCFU 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCFU 300 mg/day orally from day 14 for a year, plus intravenous mitomycin C (MMC) 6 mg/m2 on day 0 and 7 after surgery.
Trial: 12465390
Drug: Intravenous mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous mitomycin C (MMC) 6 mg/m2 on day 0 and 7 after surgery.
Trial: 8554937
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg 8‐MOP
Trial: 8554937
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg 8‐MOP
Trial: 8554937
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg 8‐MOP
Trial: 8554937
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg 8‐MOP added to 300 ml platelet concentrate
Trial: 8554937
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 7.5 mg 8‐MOP over 60 min
Trial: 8554937
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of 8‐MOP
Trial: 1838256
Drug: 2% ketoconazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% ketoconazole cream (Nizoral)
Trial: 1838256
Drug: Bland cream
RxNorm normalized name: Io-Blend
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bland cream (control)
Trial: 6117584
Drug: Placebo injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injection (holiday group)
Trial: 6117584
Drug: Regular medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular medication (control group)
Trial: 29550235
Drug: Early Limited
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early Limited Formula (ELF), 10 mL of formula after each breastfeeding until copious maternal milk production
Trial: 26349843
Drug: Topical tranexamic
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical tranexamic acid (25 mg/ml)
Trial: 18236463
Drug: High-dose beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose beta interferon-1a
Trial: 15265847
Drug: Pravastatin, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin, 20 to 40 mg/d
Trial: 3470953
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (Prepidil)
Trial: 3470953
Drug: Artificial rupture
RxNorm normalized name: COLOR,ARTIFICIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artificial rupture of membranes combined with intravenous oxytocin
Trial: 20163739
Drug: Physiotherapy program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy program including exercise and manual therapy (individual sessions once a week for 10 weeks and daily home exercises)
Trial: 20163739
Drug: Physiotherapy program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiotherapy program including exercise and manual therapy
Trial: 1437342
Drug: Bovine surfactant
RxNorm normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bovine surfactant (50 mg/kg BW)
Trial: 3885671
Drug: Hydroxyprogesterone caproate
RxNorm normalized name: Hydroxyprogesterone Caproate
DrugBank: Hydroxyprogesterone caproate (DB06789)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxyprogesterone caproate (5000 mg i.m. as a loading dose followed by 1000 mg every 2 weeks for one year)
Trial: 29738817
Drug: Antimicrobial photodynamic
RxNorm normalized name: GAUZE,ANTIMICROBIAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial photodynamic therapy (aPDT) with open flap debridement (OFD)
Trial: 19794988
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg intravenous ephedrine
Trial: 11465585
Drug: BIS-guided, model-based,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS-guided, model-based, closed-loop system for propofol administration
Trial: 11465585
Drug: Manual control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual control of propofol administration using classical hemodynamic signs
Trial: 9622403
Drug: 30-minute music
RxNorm normalized name: TAGETES MINUTA FLOWER OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-minute music therapy intervention
Trial: 7878692
Drug: Erythromycin 500
RxNorm normalized name: erythromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin 500 mg orally three times a day for 6 days
Trial: 2458438
Drug: Higher-dose chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose chemotherapy (600 mg/m2 cyclophosphamide and fluorouracil, 40 mg/m2 methotrexate)
Trial: 2458438
Drug: Lower-dose chemotherapy
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose chemotherapy (300 mg/m2 cyclophosphamide and fluorouracil, 20 mg/m2 methotrexate)
Trial: 2458438
Drug: Higher-dose chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher-dose chemotherapy
Trial: 2458438
Drug: Lower-dose chemotherapy
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower-dose chemotherapy
Trial: 2458438
Drug: Crossover from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Crossover from lower-dose to higher-dose chemotherapy
Trial: 29643011
Drug: Dolutegravir (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dolutegravir (50 mg oral once a day for 56 days)
Trial: 29643011
Drug: Placebo (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (oral once a day for 56 days)
Trial: 25851628
Drug: trastuzumab and
RxNorm normalized name: pertuzumab and trastuzumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: trastuzumab and lapatinib combination
Trial: 24180295
Drug: Structured and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured and repeated multidisciplinary medication review supported by education and continuous evaluation.
Trial: 20972646
Drug: Standard protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard protein supplement; 20% of estimated nitrogen requirements for 14 days
Trial: 12354133
Drug: L‐T4 +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐T4 + I (iodized salt)
Trial: 12354133
Drug: L‐T4 alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L‐T4 alone
Trial: 8587426
Drug: ET-1 (nonselective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-1 (nonselective agonist at ETA and ETB receptors)
Trial: 8587426
Drug: ET-3 (ETB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ET-3 (ETB receptor agonist)
Trial: 8587426
Drug: Sarafotoxin S6c
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sarafotoxin S6c (ETB receptor agonist)
Trial: 333761
Drug: Live mumps
RxNorm normalized name: mumps virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live mumps vaccine from L-3 strain, single injection of 10(4)HAdU50 of mumps virus.
Trial: 333761
Drug: Live mumps
RxNorm normalized name: mumps virus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Live mumps vaccine from L-3 strain.
Trial: 12854503
Drug: Low-dose radiation
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose radiation therapy (10 fractions of 2 Gy external beam)
Trial: 1682683
Drug: Active antihypertensive
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active antihypertensive therapy (three beta-blockers and one diuretic)
Trial: 7007473
Drug: Hydroxyzine 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine 150 mg/day
Trial: 7007473
Drug: Chlorpheniramine 24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorpheniramine 24 mg/day
Trial: 31362969
Drug: Antibiotic distribution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic distribution
Trial: 29448858
Drug: 3ABVD +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3ABVD + involved-field (IF) low-dose (LD) irradiation (20 Gy) for GR1 patients with mediastinal mass or partial response after chemotherapy.
Trial: 24374068
Drug: Micronutrient treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronutrient treatment for 8 weeks
Trial: 21162840
Drug: 10 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 µg CHO hepatitis B vaccine
Trial: 21162840
Drug: 20 µg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 µg CHO hepatitis B vaccine
Trial: 12351591
Drug: Intensified CDE
RxNorm normalized name: 2,3,7,8-tetrahydroxychromeno[5,4,3-cde]chromene-5,10-dione
DrugBank: Ellagic acid (DB08846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified CDE (cyclophosphamide 1,250 mg/m(2), doxorubicin 55 mg/m(2), etoposide 125 mg/m(2) with G-CSF 5 micro g/kg/d)
Trial: 12351591
Drug: Standard CDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard CDE (cyclophosphamide 1,000 mg/m(2), doxorubicin 45 mg/m(2), etoposide 100 mg/m(2))
Trial: 9690802
Drug: Steroid therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Steroid therapy (specific dosage and duration not mentioned)
Trial: 7710467
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (0.5 mg)
Trial: 2511611
Drug: Test formulation
RxNorm normalized name: mumps skin test antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Test formulation of phenoxymethylpenicillin suspension
Trial: 2511611
Drug: Standard formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard formulation of phenoxymethylpenicillin suspension
Trial: 25954938
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy (CBT) for 12 weeks
Trial: 25954938
Drug: Escitalopram (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Escitalopram (10 to 20 mg) for 12 weeks
Trial: 22900665
Drug: Traditional oral
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional oral healthcare information (Control)
Trial: 21810897
Drug: Captopril and
RxNorm normalized name: captopril and diuretics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril and atenolol as monotherapy
Trial: 11282268
Drug: Intravenous pefloxacin
RxNorm normalized name: pefloxacin
DrugBank: Pefloxacin (DB00487)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous pefloxacin (800 mg)
Trial: 8292723
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg of vitamin K1 orally in addition to the usual warfarin dose (group B)
Trial: 8292723
Drug: Discontinued warfarin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discontinued warfarin for one day (group A)
Trial: 8292723
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups continued with their usual dose of warfarin after day 1
Trial: 22446297
Drug: T-614 group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 group 2 (25mg twice daily)
Trial: 22446297
Drug: MTX group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX group (10 mg/week for the first 4 weeks and 15 mg/week for the subsequent 20 weeks)
Trial: 22446297
Drug: T-614 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 (50 μg/ml)
Trial: 22446297
Drug: T-614 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 (5 μg/ml or more)
Trial: 22446297
Drug: T-614 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T-614 treatment
Trial: 20173715
Drug: Short prophylactic
RxNorm normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short prophylactic therapy (2 grams of amoxicillin 1 hour before the procedure and 1 gram 6 hours after surgery)
Trial: 20173715
Drug: Long postoperative
RxNorm normalized name: long pepper extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long postoperative regimen (1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hours for 4 days)
Trial: 14664688
Drug: Fixed model
RxNorm normalized name: Humalog Mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed model approach for evaluating therapy studies
Trial: 10641419
Drug: Comprehensive periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Comprehensive periodontal treatment with emphasis on oral hygiene
Trial: 10641419
Drug: Nifedipine administration
RxNorm normalized name: Nifedipine
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nifedipine administration
Trial: 8889288
Drug: D-cycloserine 5
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine 5 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Trial: 8889288
Drug: D-cycloserine 15
RxNorm normalized name: D-(+)-cycloserine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-cycloserine 15 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Trial: 8889288
Drug: Placebo +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo + molindone 150 mg p.o. q.d.
Trial: 6362553
Drug: Amoxicillin‐clavulanic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin‐clavulanic acid (A‐C) for 10 days
Trial: 23972694
Drug: GXR administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GXR administered in the morning (1-4 mg/d)
Trial: 23972694
Drug: GXR administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GXR administered in the evening (1-4 mg/d)
Trial: 27550184
Drug: Placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered twice daily
Trial: 16761155
Drug: Day hospital
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Day hospital nurses handling antineoplastic drugs
Trial: 12409635
Drug: Diet therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diet therapy (n = 810)
Trial: 9836156
Drug: Natural drying
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natural drying of the umbilical site without special treatment
Trial: 2910758
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg twice daily for 1 week)
Trial: 2910758
Drug: Cimetidine (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (50 mg/kg body wt) in rats
Trial: 30360748
Drug: Oral Levofloxacin
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Levofloxacin (TAVANEX), 750 mg, once daily for five days
Trial: 30360748
Drug: Parenteral Ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral Ceftriaxone 1gr BD plus oral Azithromycin (250 mg, once daily) for seven to ten days
Trial: 18824931
Drug: Aspirin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (10 mg x kg(‐1))
Trial: 14707397
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) 750 mg/day for 6 months
Trial: 7676787
Drug: Propofol with
RxNorm normalized name: propofol with medium chain triglycerides 10 mg/mL intravenous emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol with 1.0 mg alfentanil
Trial: 2305332
Drug: Pivampicillin (700
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pivampicillin (700 mg twice daily for 9 days)
Trial: 2305332
Drug: Doxycycline (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxycycline (200 mg on the first day, then 100 mg daily plus one placebo tablet for 9 days)
Trial: 24457604
Drug: UPA 5
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: UPA 5 mg
Trial: 24457604
Drug: UPA 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UPA 10 mg
Trial: 22980429
Drug: 3% acetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3% acetic acid gel
Trial: 17263884
Drug: No IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No IL-2 therapy (Control)
Trial: 1752914
Drug: liquid-filled soft
RxNorm normalized name: Foster & Thrive Ibuprofen 200mg Liquid-Filled Softgel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liquid-filled soft gelatin capsules (TL)
Trial: 11916761
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg FeSO4 twice daily for 6 weeks
Trial: 11916761
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 6 weeks
Trial: 9864077
Drug: Lithium (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium (serum drug level 0.6+/‐0.1 mmol/L)
Trial: 9864077
Drug: Carbamazepine (serum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbamazepine (serum drug level 6.1+/‐1.3 microg/mL)
Trial: 8471984
Drug: Cyclophosphamide with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide with low dose alpha-interferon (IFN)
Trial: 25525163
Drug: Dietary supplement
RxNorm normalized name: dietary supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dietary supplement (vitamin C, E, zinc, lutein/zeaxanthin, selenium, taurine, Aronia extract, omega-3 free fatty acids)
Trial: 22849546
Drug: Conventional triple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional triple therapy (10 days of lansoprazole, amoxicillin, and clarithromycin)
Trial: 17432784
Drug: Azithromycin 500
RxNorm normalized name: azithromycin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 500 mg once daily for 3 days after extraction
Trial: 17432784
Drug: Physiologic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physiologic saline 3 times daily from 24 hours after extraction for 7 days
Trial: 11870500
Drug: Cimetidine (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (800 mg day(-1) orally) + 5-fluorouracil (200 mg day(-1))
Trial: 7263877
Drug: Rational-emotive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rational-emotive therapy (RET)
Trial: 28183585
Drug: Longitudinal view
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Longitudinal view (group L)
Trial: 24132814
Drug: SOMA (somatostatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOMA (somatostatin 300 μg/hour and heparin 70 mIE/kg/min)
Trial: 24132814
Drug: SALINE (saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SALINE (saline infusion)
Trial: 20682548
Drug: Short-term gemcitabine
RxNorm normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Short-term gemcitabine and paclitaxel chemotherapy (arm A)